BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/24/2025 3:48:37 AM | Browse: 107 | Download: 407
 |
Received |
|
2025-02-10 08:18 |
|
Peer-Review Started |
|
2025-02-11 08:25 |
|
First Decision by Editorial Office Director |
|
2025-03-25 07:31 |
|
Return for Revision |
|
2025-03-25 07:31 |
|
Revised |
|
2025-04-07 12:37 |
|
Publication Fee Transferred |
|
2025-04-09 02:58 |
|
Second Decision by Editor |
|
2025-07-28 05:46 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-08-04 09:01 |
|
Articles in Press |
|
2025-08-04 09:01 |
|
Edit the Manuscript by Language Editor |
|
2025-08-12 20:08 |
|
Typeset the Manuscript |
|
2025-09-06 15:04 |
|
Publish the Manuscript Online |
|
2025-09-24 03:48 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Basic Study |
| Article Title |
Quercetin pre-treated umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease via IL-10/JAK2/STAT3 signaling
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Meng-Yue Shi, Lian Liu and Fu-Yuan Yang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Science and Technology Research Project of Hubei Province |
2021CFB210 |
| Central Guiding Local Science and Technology Development Fund Project (Science and Technology Department of Xizang Autonomous Region) |
XZ202401YD0002C |
|
| Corresponding Author |
Fu-Yuan Yang, PhD, Department of Anaesthesiology, The First Affiliated Hospital of Yangtze University, No. 55 Jianghan North Road, Shashi District, Jingzhou 434020, Hubei Province, China. ivansblue@sina.com |
| Key Words |
Quercetin; Human umbilical cord-derived mesenchymal stem cells; Inflammatory bowel disease; Interleukin-10; Janus kinase/signal transducer and activator of transcription/suppressor of cytokine signaling signal |
| Core Tip |
Quercetin (QUR) pretreatment enhanced the viability of human umbilical cord-derived mesenchymal stem cells (hUCMSCs), which may improve their immune regulatory ability. Intraperitoneal injection of QUR-hUCMSCs effectively alleviated inflammation in 2,4,6-trinitrobenzenesulfonic acid mice, and the therapeutic effect was superior to untreated hUCMSCs. QUR-hUCMSCs treatment significantly enhanced interleukin-10 expression in 2,4,6-trinitrobenzenesulfonic acid mice. QUR-hUCMSCs inhibit inflammatory bowel disease inflammation by regulating the interleukin-10/Janus kinase/signal transducer and activator of transcription signaling pathway. |
| Publish Date |
2025-09-24 03:48 |
| Citation |
Shi MY, Liu L, Yang FY. Quercetin pre-treated umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease via IL-10/JAK2/STAT3 signaling. World J Stem Cells 2025; 17(9): 105896 |
| URL |
https://www.wjgnet.com/1948-0210/full/v17/i9/105896.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v17.i9.105896 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
